Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Researchers led by Marta Barrachina, Institute of Neuropathology of the Bellvitge Biomedical Research Institute (IDIBELL) have identified a new subgroup of patients suffering from schizophrenia characterized by motor disorders.
The study, which was conducted in collaboration with the research team Mairena Martin at the University of Castilla La Mancha at Ciudad Real and clinical researchers of the Health Park Sant Joan de Deu at Sant Boi de Llobregat, has been published in the online edition of the Journal of Psychiatric Research and was funded by the TV3 Marathon in its 2008 edition.
Schizophrenia is a serious mental illness. From a clinical point of view is considered grouping several diseases that are not well defined or characterized by biomarkers.
Barrachina team studies the A2A adenosine receptor, which is highly expressed in the basal ganglia at the central nervous system and is involved in the control of movement. Furthermore this protein inhibits the activity of dopamine D2 receptor, hyperactivated in schizophrenia patients and typical antipsychotics target.
"We studied the post- mortem brains of patients," explains Barrachina "and we found that 50% had very low levels of adenosine A2A receptor. Interestingly, when comparing these data with clinical information provided by the clinical investigators of the study, we note that these patients had motor disorders." "In addition, we identified an epigenetic mechanism associated with the decreased receptor expression."
According to the researcher, this finding allows to "identify a new subset of schizophrenia patients with motor disorders."
Proposal for combined therapy
This study opens the door to a clinical trial, based on radioimage, which would detect the levels of this protein and identify these patients and also to confirm the results obtained in the postmortem brains of patients. Barrachina team proposes to apply a specific combination therapy of antipsychotics and agonists of A2A adenosine. "Thus, the activity of adenosine A2A receptor will be favoured, reducing the dose of antipsychotics."
Villar-Menéndez I, Díaz-Sánchez S, Blanch M, Albasanz JL, Pereira-Veiga T, Monje A, Planchat LM, Ferrer I, Martín M and Barrachina M. Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia. Journal Psyquiatric Research (2014),
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Schizophrenia category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
IDIBELL-Bellvitge Biomedical Research Institute. "Subgroup of schizophrenia patients with motor disorders identified." Medical News Today. MediLexicon, Intl., 31 Jan. 2014. Web.
8 Mar. 2014. <http://www.medicalnewstoday.com/releases/271922>
IDIBELL-Bellvitge Biomedical Research Institute. (2014, January 31). "Subgroup of schizophrenia patients with motor disorders identified." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271922.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.